Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Navigating Cisplatin Shortages and the Need for Legislation

August 24, 2023
By Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC
Commentary
Video

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, believes that national legislation can help to resolve the United States’ current dearth of cisplatin, as well as prevent future problems.

Several factors have contributed to the ongoing cisplatin shortage, ranging from manufacturing issues, supply chain difficulties, and even prioritizing the production of other branded cancer therapies over generics, according to Kirollos Hanna, PharmD, BCPS, BCOP, FACCC.

During an interview with CancerNetwork®, Hanna, director of Minnesota Oncology Pharmacy Services, and assistant professor of Pharmacy at the Mayo Clinic provided insight into why the shortages have occurred but also hypothesized potential solutions. In particular, he stated that regulatory authorities can learn from the current shortage and that legislation may play a role in avoiding future shortages.

Transcript:

This cisplatin shortage stemmed from [a quality control issue with] one of the largest manufacturers that make about 70% to 80% of the cisplatin in the country. The FDA had to shut down that plant, and [the manufacturer is] working with them. All of a sudden, [for] other generic manufacturers that were generally responsible for making about 20% of allocations for the country, the ask is much higher, and they can’t produce accordingly. We have seen numerous things that have led to shortages, sometimes pandemic related, sometimes pre-pandemic. We’ve been dealing with shortages for years now.

What I find interesting is if you look at [drugs like] Keytruda [pembrolizumab], Opdivo [nivolumab], or Darzalex [daratumumab], if you look at these branded therapeutics—these monoclonal antibodies where so much money is invested from these larger pharmaceutical companies—we will never find a shortage of these drugs. Why is it that these critical therapeutics that in many areas are tied to curative intent regimens [have shortages]? Why do we not invest in those plants, [and] organizations to alleviate the situation from ever happening?

Why don’t we partner with different manufacturers outside of the United States, similar to what we did with China to [help alleviate] the cisplatin shortage? Why do we wait until it gets so critical? For something of this magnitude, for there to be a true resolution, there needs to be something that comes down from legislation that is national and governs all. Sometimes because of the cheap cost of generic therapeutics, a lot of time and money, and effort aren’t invested in that because the ROI [return on investment], isn’t there, as you see with your big, branded products.

That’s where I do think that needs to happen from a national level for this situation to resolve now. As healthcare providers, the number of times we’ve seen this should have people think a little bit differently about shortages.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
“Dendritic cell vaccines, CAR T-cell therapy, and things of that nature are holding some promise,” said Andrew Brenner, MD, PhD.
Related Content

Vegetarian Lifestyle May Promote Lower Risk of Cancer

Vegetarian Lifestyle May Promote Lower Risk of Cancer

Ariana Pelosci
June 28th 2025
Article

The Adventist Health Study found that patients who were vegetarians had a lower risk of medium-frequency cancers.


Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of pharmacology Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.


PATHFINDER 2 data build upon bolstered cancer detection rates by the multi-cancer early detection test found in a previously published PATHFINDER study.

Galleri Early Detection Test May Improve Cancer Detection vs SOC Alone

Roman Fabbricatore
June 26th 2025
Article

PATHFINDER 2 data build upon bolstered cancer detection rates by the multicancer early detection test found in a previously published PATHFINDER study.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


FDA Grants Fast-Track Designation to RAD101 Imaging for Brain Metastases

FDA Grants Fast-Track Designation to RAD101 Imaging for Brain Metastases

Tim Cortese
June 12th 2025
Article

The developer plans to share top-line results for RAD101 in various solid tumors from the supporting phase 2b trial in the second half of 2025.


China’s CDE Accepts Marketing Application for Pimicotinib in TGCT

China’s CDE Accepts Marketing Application for Pimicotinib in TGCT

Tim Cortese
June 10th 2025
Article

In the phase 3 MANEUVER trial, pimicotinib improved the objective response rate vs placebo in patients with tenosynovial giant cell tumor.

Related Content

Vegetarian Lifestyle May Promote Lower Risk of Cancer

Vegetarian Lifestyle May Promote Lower Risk of Cancer

Ariana Pelosci
June 28th 2025
Article

The Adventist Health Study found that patients who were vegetarians had a lower risk of medium-frequency cancers.


Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of pharmacology Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.


PATHFINDER 2 data build upon bolstered cancer detection rates by the multi-cancer early detection test found in a previously published PATHFINDER study.

Galleri Early Detection Test May Improve Cancer Detection vs SOC Alone

Roman Fabbricatore
June 26th 2025
Article

PATHFINDER 2 data build upon bolstered cancer detection rates by the multicancer early detection test found in a previously published PATHFINDER study.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


FDA Grants Fast-Track Designation to RAD101 Imaging for Brain Metastases

FDA Grants Fast-Track Designation to RAD101 Imaging for Brain Metastases

Tim Cortese
June 12th 2025
Article

The developer plans to share top-line results for RAD101 in various solid tumors from the supporting phase 2b trial in the second half of 2025.


China’s CDE Accepts Marketing Application for Pimicotinib in TGCT

China’s CDE Accepts Marketing Application for Pimicotinib in TGCT

Tim Cortese
June 10th 2025
Article

In the phase 3 MANEUVER trial, pimicotinib improved the objective response rate vs placebo in patients with tenosynovial giant cell tumor.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.